No Data
No Data
Lilly, Gilead, Amgen Started at Outperform by Bernstein
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $335 to $381
Amgen Says Phase 3 Uplizna Trial in Generalized Myasthenia Gravis Meets Primary Endpoint
Express News | Amgen Presents Positive Phase 3 Data for Uplizna® (Inebilizumab-Cdon) in Generalized Myasthenia Gravis (Gmg) at Aanem 2024
DBS Maintains Amgen(AMGN.US) With Buy Rating
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
No Data
No Data
amiable Llama_6295 : hippee hippee